News|Videos|August 22, 2024 (Updated: August 29, 2024)

Supplements and Featured Publications

  • Spotlighting the Evolution of NF2-Related Schwannomatosis Management Strategies
  • Volume 1
  • Issue 1

Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors

Scott Plotkin, MD, reviews data from a phase II study on brigatinib, a multi tyrosine kinase inhibitor, across various tumor types in patients with NF2-related schwannomatosis.


Related to this article